Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma

【Treatment of Urothelial Carcinoma】 Treatment for urothelial carcinoma includes surgery, chemotherapy (anticancer drugs), and radiation therapy. Chemotherapy is generally used when metastasis has already occurred at diagnosis and surgery is not curative (metastatic urothelial carcinoma) or when the cancer recurs after local therapy such as surgery or radiation therapy (recurrent urothelial carcinoma). Although there are several recommended treatments for urothelial carcinoma, the options are often limited by side effects and other factors, and these treatments may not be fully effective. Ther

Trial Details

NCT ID
NCT06983210
Phase
PHASE2
Sponsor
Nagoya University
Status
RECRUITING
Cancer Type
Bladder Cancer
Interventions
  • Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy
Locations (sample)
  • Nagoya, Aichi-ken, Japan|35.18147,136.90641

Key Eligibility Criteria

  • Patients who have been histologically or cytologically diagnosed with urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra based o…
  • Patients who have not received prior treatment for unresectable or recurrent urothelial carcinoma
  • Patients with measurable lesions according to RECIST version 1.1 on the CT at screening
  • Patients with an ECOG PS of 0-1 at screening, who are able to take oral medication

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →